North Star Asset Management Inc. boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 32.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,549 shares of the biotechnology company’s stock after purchasing an additional 5,040 shares during the period. North Star Asset Management Inc. owned 0.06% of Repligen Corporation worth $852,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Eaton Vance Management acquired a new position in Repligen Corporation during the second quarter valued at approximately $529,000. Benin Management CORP acquired a new position in Repligen Corporation during the second quarter valued at approximately $207,000. Jennison Associates LLC acquired a new position in Repligen Corporation during the second quarter valued at approximately $291,000. Legal & General Group Plc boosted its position in Repligen Corporation by 15.3% during the second quarter. Legal & General Group Plc now owns 68,677 shares of the biotechnology company’s stock valued at $2,845,000 after purchasing an additional 9,121 shares during the last quarter. Finally, Karp Capital Management Corp acquired a new position in Repligen Corporation during the first quarter valued at approximately $506,000. 97.91% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently commented on the company. Janney Montgomery Scott increased their price target on Repligen Corporation from $42.00 to $47.00 in a research report on Friday, June 23rd. TheStreet raised Repligen Corporation from a “c+” rating to a “b-” rating in a research report on Friday, August 11th. BidaskClub raised Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Thursday, October 5th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $40.00 price target on shares of Repligen Corporation in a research report on Thursday, September 14th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $45.40.

Repligen Corporation (NASDAQ RGEN) traded up 0.60% during mid-day trading on Friday, reaching $38.50. The company’s stock had a trading volume of 153,786 shares. The firm has a 50 day moving average price of $41.21 and a 200 day moving average price of $39.72. The company has a market cap of $1.44 billion, a price-to-earnings ratio of 75.34 and a beta of 1.18. Repligen Corporation has a 52-week low of $26.16 and a 52-week high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The firm had revenue of $32.40 million for the quarter, compared to the consensus estimate of $31.72 million. During the same quarter in the previous year, the business earned $0.16 EPS. The company’s revenue was up 11.0% compared to the same quarter last year. Equities research analysts anticipate that Repligen Corporation will post $0.59 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “North Star Asset Management Inc. Buys 5,040 Shares of Repligen Corporation (RGEN)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/15/north-star-asset-management-inc-buys-5040-shares-of-repligen-corporation-rgen.html.

Repligen Corporation Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.